Wolverine Trading, LLC Cassava Sciences Inc Call Options Transaction History

Wolverine Trading, LLC

11 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q1 2024 May 15, 2024	BUY	$18.44 - $26.41 $435,184 - $623,276	23,600 New	23,600 $478,000
Q3 2023 Nov 15, 2023	BUY	$16.64 - $25.32 $406,016 - $617,808	24,400 Added 60.7%	64,600 $1.07 Million
Q2 2023 Aug 23, 2023	SELL	$21.59 - $27.88 $207,264 - $267,648	-9,600 Reduced 19.28%	40,200 $985,000
Q1 2023 May 15, 2023	SELL	$23.46 - $36.44 $1.06 Million - $1.65 Million	-45,300 Reduced 47.63%	49,800 $1.2 Million
Q4 2022 Feb 14, 2023	BUY	$27.82 - $44.16 $2.65 Million - $4.2 Million	95,100 New	95,100 $2.81 Million

Q2 2022 Aug 15, 2022	SELL	$17.22 - $38.47 $36,162 - $80,787	-2,100 Reduced 2.42%	84,500 $2.51 Million
Q1 2022 May 16, 2022	SELL	$32.6 - $53.05 $648,740 - $1.06 Million	-19,900 Reduced 18.69%	86,600 $3.34 Million
Q4 2021 Feb 14, 2022	SELL	$36.77 - $90.91 $2.33 Million - $5.75 Million	-63,300 Reduced 37.28%	106,500 $4.66 Million
Q3 2021 Nov 12, 2021	BUY	$41.79 - $135.3 $2.64 Million - $8.55 Million	63,200 Added 59.29%	169,800 $10.6 Million
Q2 2021 Aug 06, 2021	BUY	$32.15 - $89.72 $890,555 - $2.49 Million	27,700 Added 35.11%	106,600 $8.85 Million
Q1 2021 May 14, 2021	BUY	$7.09 - $87.95 $559,401 - $6.94 Million	78,900 New	78,900 $3.47 Million

172

11.3M

1.61M

1.43M

Ticker SAVA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 40,097,900
Market Cap $410M
Description
Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's...

Get notified when there are updates to the investment portfolio of Wolverine Trading, LLC, based on Form 13F filings with the SEC.

Stay updated on Wolverine Trading, LLC with notifications on news.